Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $186.94M.
ENTERPRISE VALUE (EV)
$186.94M
Eupraxia Pharmaceuticals Inc.
Market Cap
$267.51M
Enterprise Value (EV)
$186.94M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $267.51M | $186.94M |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.87M | $179.78M |
| OraSure Technologies, Inc. (OSUR)vs › | $268.17M | $119.68M |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.28M | $235.08M |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $262.65M | $176.63M |
| Palisade Bio, Inc. (PALI)vs › | $261.22M | $136.05M |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | $74.91M |
| Scribe Therapeutics Inc. (SCTX)vs › | $274.77M | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | $273.92M |
| Fate Therapeutics, Inc. (FATE)vs › | $277.46M | $320.70M |
Market Cap
$267.51M
Total Debt
$0.00
Cash
$80.56M
Enterprise Value
$186.94M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
